MVP
Major vault protein
Also known as: LRP, MVP_HUMAN, VAULT1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14764
- Gene
- MVP
- Ensembl
- ENSG00000013364
- Chromosome
- 16
- Canonical length
- 893 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins, Transporters
- Subcellular location
- Cytosol
OverviewNCBI Gene
This gene encodes the major component of the vault complex. Vaults are multi-subunit ribonucleoprotein structures that may be involved in nucleo-cytoplasmic transport. The encoded protein may play a role in multiple cellular processes by regulating the MAP kinase, JAK/STAT and phosphoinositide 3-kinase/Akt signaling pathways. The encoded protein also plays a role in multidrug resistance, and expression of this gene may be a prognostic marker for several types of cancer. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, May 2012]
Canonical amino-acid sequenceUniProt
893 residues, UniProt reviewed canonical sequence.
>Q14764|MVP
1 MATEEFIIRI PPYHYIHVLD QNSNVSRVEV GPKTYIRQDN ERVLFAPMRM VTVPPRHYCT
61 VANPVSRDAQ GLVLFDVTGQ VRLRHADLEI RLAQDPFPLY PGEVLEKDIT PLQVVLPNTA
121 LHLKALLDFE DKDGDKVVAG DEWLFEGPGT YIPRKEVEVV EIIQATIIRQ NQALRLRARK
181 ECWDRDGKER VTGEEWLVTT VGAYLPAVFE EVLDLVDAVI LTEKTALHLR ARRNFRDFRG
241 VSRRTGEEWL VTVQDTEAHV PDVHEEVLGV VPITTLGPHN YCVILDPVGP DGKNQLGQKR
301 VVKGEKSFFL QPGEQLEQGI QDVYVLSEQQ GLLLRALQPL EEGEDEEKVS HQAGDHWLIR
361 GPLEYVPSAK VEVVEERQAI PLDENEGIYV QDVKTGKVRA VIGSTYMLTQ DEVLWEKELP
421 PGVEELLNKG QDPLADRGEK DTAKSLQPLA PRNKTRVVSY RVPHNAAVQV YDYREKRARV
481 VFGPELVSLG PEEQFTVLSL SAGRPKRPHA RRALCLLLGP DFFTDVITIE TADHARLQLQ
541 LAYNWHFEVN DRKDPQETAK LFSVPDFVGD ACKAIASRVR GAVASVTFDD FHKNSARIIR
601 TAVFGFETSE AKGPDGMALP RPRDQAVFPQ NGLVVSSVDV QSVEPVDQRT RDALQRSVQL
661 AIEITTNSQE AAAKHEAQRL EQEARGRLER QKILDQSEAE KARKELLELE ALSMAVESTG
721 TAKAEAESRA EAARIEGEGS VLQAKLKAQA LAIETEAELQ RVQKVRELEL VYARAQLELE
781 VSKAQQLAEV EVKKFKQMTE AIGPSTIRDL AVAGPEMQVK LLQSLGLKST LITDGSTPIN
841 LFNTAFGLLG MGPEGQPLGR RVASGPSPGE GISPQSAQAP QAPGDNHVVP VLRLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MVP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 176 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 176 nTPM
- colon: 162 nTPM
- small intestine: 157 nTPM
- duodenum: 146 nTPM
- lung: 120 nTPM
- spleen: 112 nTPM
Single-cell type
- enterocytes: 508 nCPM
- colonocytes: 467 nCPM
- syncytiotrophoblasts: 391 nCPM
- alveolar cells type 2: 247 nCPM
- enteric transient amplifying cells: 192 nCPM
- foveolar cells: 190 nCPM
Immune cell
- intermediate monocyte: 214 nTPM
- non-classical monocyte: 205 nTPM
- total PBMC: 164 nTPM
- neutrophil: 161 nTPM
- classical monocyte: 141 nTPM
- myeloid DC: 113 nTPM
Brain region
- medulla oblongata: 68 nTPM
- thalamus: 68 nTPM
- white matter: 55 nTPM
- midbrain: 52 nTPM
- basal ganglia: 50 nTPM
- pons: 50 nTPM
ReferencesPubMed · IEDB
Publications for MVP from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
1 publication
- Major vault protein/lung resistance related protein: a novel biomarker for rheumatoid arthritis.
2021 · Clin Exp Rheumatol · RCR 0.8 · 11 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.73
- gnomAD pLI
- 0
- gnomAD missense Z
- 2.02
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell population proliferation
- ERBB signaling pathway
- intracellular signal transduction
- mRNA transport
- negative regulation of epidermal growth factor receptor signaling pathway
- protein transport
- protein activation cascade
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Band 7/SPFH domain superfamily
- Major vault protein, N-terminal
- Major vault protein, shoulder domain
- Major vault protein
- Major vault protein repeat domain 3
- Major vault protein repeat domain 2
- Major vault protein repeat domain 4
- Major vault protein repeat domain
- Major vault protein repeat domain superfamily
- Major vault protein repeat domain 2 superfamily
- Major Vault Protein repeat domain
- Shoulder domain
- Major Vault Protein repeat domain
- Major Vault Protein Repeat domain
- Major Vault Protein repeat domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MVP in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MVP as an antibody target. Whether an autoantibody or antibody against MVP could matter depends on whether native MVP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MVP is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MVP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...